Artivion, Inc. (NYSE:AORT) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Artivion, Inc. (NYSE:AORT) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $44.1667.

Several research analysts have weighed in on the company. Stifel Nicolaus set a $45.00 price target on Artivion in a report on Monday, June 1st. Needham & Company LLC restated a “buy” rating and set a $44.00 price objective on shares of Artivion in a report on Monday, July 20th. Citizens Jmp lowered their price objective on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research report on Friday, May 8th. LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a research note on Friday, April 10th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $36.00 target price on shares of Artivion in a research report on Tuesday, June 16th.

Insider Activity at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the transaction, the senior vice president owned 60,259 shares of the company’s stock, valued at $1,247,361.30. This represents a 42.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Artivion

Several hedge funds have recently modified their holdings of AORT. Caitong International Asset Management Co. Ltd purchased a new stake in Artivion in the third quarter valued at approximately $27,000. Rockefeller Capital Management L.P. increased its position in Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares during the last quarter. Larson Financial Group LLC raised its stake in Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares during the period. KBC Group NV purchased a new position in Artivion during the fourth quarter worth approximately $65,000. Finally, First Horizon Corp boosted its holdings in shares of Artivion by 199.4% in the 4th quarter. First Horizon Corp now owns 1,602 shares of the company’s stock valued at $73,000 after purchasing an additional 1,067 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Stock Up 0.4%

Shares of NYSE AORT opened at $27.67 on Friday. Artivion has a 1 year low of $19.16 and a 1 year high of $48.25. The firm’s 50 day moving average price is $23.01 and its 200 day moving average price is $31.73. The firm has a market cap of $1.34 billion, a P/E ratio of 115.30 and a beta of 1.26. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.